PL379541A1 - Granulki zawierające chlorowodorek venlafaxiny - Google Patents

Granulki zawierające chlorowodorek venlafaxiny

Info

Publication number: PL379541A1
Authority: PL; Poland
Prior art keywords: weight; pellets; venlafaxine hydrochloride; pellets containing; chloride
Prior art date: 2003-10-10

Application number

PL379541A

Other languages

English (en)

Inventor

Pal Fekete

Tibor Korbely

Agnes Bozso

Eszter Moricz

Original Assignee

Egis Gyogyszergyar Rt.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2004-10-08

Publication date

2006-10-02

2004-10-08 Application filed by Egis Gyogyszergyar Rt. filed Critical Egis Gyogyszergyar Rt.

2006-10-02 Publication of PL379541A1 publication Critical patent/PL379541A1/pl

Links

239000008188 pellet Substances 0.000 title abstract 4
229960002416 venlafaxine hydrochloride Drugs 0.000 title abstract 3
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title abstract 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
238000013270 controlled release Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
238000005453 pelletization Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000001103 potassium chloride Substances 0.000 abstract 1
235000011164 potassium chloride Nutrition 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL379541A 2003-10-10 2004-10-08 Granulki zawierające chlorowodorek venlafaxiny PL379541A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU0303382A HUP0303382A2 (hu)	2003-10-10	2003-10-10	Venlafaxin-hidroklorid-tartalmú pelletek

Publications (1)

Publication Number	Publication Date
PL379541A1 true PL379541A1 (pl)	2006-10-02

Family

ID=90001704

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL379541A PL379541A1 (pl)	2003-10-10	2004-10-08	Granulki zawierające chlorowodorek venlafaxiny
PL04791654T PL1677777T3 (pl)	2003-10-10	2004-10-08	Granulki zawierające chlorowodorek venlafaxiny

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL04791654T PL1677777T3 (pl)	2003-10-10	2004-10-08	Granulki zawierające chlorowodorek venlafaxiny

Country Status (22)

Country	Link
EP (1)	EP1677777B1 (pl)
CN (1)	CN1882321B (pl)
AT (1)	ATE359771T1 (pl)
AU (1)	AU2004280132B2 (pl)
BG (1)	BG109539A (pl)
CY (1)	CY1106693T1 (pl)
CZ (1)	CZ2006269A3 (pl)
DE (1)	DE602004006009T2 (pl)
DK (1)	DK1677777T3 (pl)
EA (1)	EA009695B1 (pl)
ES (1)	ES2285538T3 (pl)
HR (2)	HRP20060136A2 (pl)
HU (1)	HUP0303382A2 (pl)
IL (1)	IL174830A (pl)
NO (1)	NO20062082L (pl)
PL (2)	PL379541A1 (pl)
PT (1)	PT1677777E (pl)
RS (2)	RS52150B (pl)
SI (1)	SI1677777T1 (pl)
SK (1)	SK50442006A3 (pl)
UA (1)	UA82268C2 (pl)
WO (1)	WO2005034930A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE526950T1 (de)	1999-10-29	2011-10-15	Euro Celtique Sa	Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
EP2283829A1 (en)	2000-10-30	2011-02-16	Euro-Celtique S.A.	Controlled release hydrocodone formulations
IL146462A (en)	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2007016315A2 (en) *	2005-07-28	2007-02-08	Dr. Reddy's Laboratories Ltd.	Extended release venlafaxine compositions
WO2007135470A1 (en) *	2006-05-19	2007-11-29	EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság	Process for the preparation and surface coating of pellets
US8445018B2 (en)	2006-09-15	2013-05-21	Cima Labs Inc.	Abuse resistant drug formulation
WO2011143119A1 (en) *	2010-05-11	2011-11-17	Cima Labs Inc.	Alcohol-resistant extended release dosage forms comprising venlafaxine
CA2798702A1 (en)	2010-05-11	2011-11-17	Cima Labs Inc.	Alcoholresistant metoprolol-containing extended-release oral dosage forms
US20160367502A1 (en) *	2012-12-19	2016-12-22	Ratiopharm Gmbh	Film coated pellets
CN103893151B (zh) *	2012-12-31	2018-04-27	石药集团中奇制药技术（石家庄）有限公司	一种盐酸文拉法辛缓释胶囊及其制备方法
US20150118300A1 (en)	2013-10-31	2015-04-30	Cima Labs Inc.	Immediate Release Abuse-Deterrent Granulated Dosage Forms
US12589083B2 (en)	2019-05-07	2026-03-31	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (en)	2019-05-07	2023-01-11	Clexio Biosciences Ltd.	ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
CN114028577B (zh) *	2021-10-20	2024-07-02	珠海市东辰制药有限公司	一种二氧化硅丸芯及其制备方法
CN119868294B (zh) *	2024-11-08	2026-02-03	迪沙药业集团有限公司	一种利格列汀药物组合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1331003B1 (en) *	1996-03-25	2015-08-26	Wyeth LLC	Extended release formulation containing venlafaxine
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
UA77145C2 (en) *	1997-11-05	2006-11-15	Wyeth Corp	Extended release dosage formulation
CN1334080A (zh) *	2001-07-25	2002-02-06	成都康弘制药有限公司	盐酸万拉法新缓释片及其制备方法
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) *	2002-03-28	2003-10-13	Synthon B.V.	Extended release venlafaxine formulations

2003
- 2003-10-10 HU HU0303382A patent/HUP0303382A2/hu unknown
2004
- 2004-08-10 UA UAA200605099A patent/UA82268C2/uk unknown
- 2004-10-08 RS RS20060252A patent/RS52150B/sr unknown
- 2004-10-08 EP EP04791654A patent/EP1677777B1/en not_active Expired - Lifetime
- 2004-10-08 EA EA200600675A patent/EA009695B1/ru not_active IP Right Cessation
- 2004-10-08 PL PL379541A patent/PL379541A1/pl not_active IP Right Cessation
- 2004-10-08 RS YUP-2006/0252A patent/RS20060252A/sr unknown
- 2004-10-08 PT PT04791654T patent/PT1677777E/pt unknown
- 2004-10-08 CN CN2004800330326A patent/CN1882321B/zh not_active Expired - Fee Related
- 2004-10-08 HR HR20060136A patent/HRP20060136A2/xx not_active Application Discontinuation
- 2004-10-08 DK DK04791654T patent/DK1677777T3/da active
- 2004-10-08 WO PCT/HU2004/000095 patent/WO2005034930A1/en not_active Ceased
- 2004-10-08 DE DE602004006009T patent/DE602004006009T2/de not_active Expired - Lifetime
- 2004-10-08 ES ES04791654T patent/ES2285538T3/es not_active Expired - Lifetime
- 2004-10-08 PL PL04791654T patent/PL1677777T3/pl unknown
- 2004-10-08 AU AU2004280132A patent/AU2004280132B2/en not_active Ceased
- 2004-10-08 HR HR20070322T patent/HRP20070322T3/xx unknown
- 2004-10-08 AT AT04791654T patent/ATE359771T1/de active
- 2004-10-08 SK SK5044-2006A patent/SK50442006A3/sk unknown
- 2004-10-08 SI SI200430364T patent/SI1677777T1/sl unknown
- 2004-10-08 CZ CZ20060269A patent/CZ2006269A3/cs unknown
2006
- 2006-04-06 IL IL174830A patent/IL174830A/en not_active IP Right Cessation
- 2006-05-09 NO NO20062082A patent/NO20062082L/no unknown
- 2006-05-10 BG BG109539A patent/BG109539A/bg unknown
2007
- 2007-07-02 CY CY20071100874T patent/CY1106693T1/el unknown

Also Published As

Publication number	Publication date
AU2004280132B2 (en)	2009-10-22
PT1677777E (pt)	2007-06-21
CZ2006269A3 (cs)	2006-07-12
UA82268C2 (uk)	2008-03-25
EA200600675A1 (ru)	2006-08-25
CN1882321B (zh)	2011-06-08
HUP0303382A2 (hu)	2005-08-29
IL174830A (en)	2010-04-15
EP1677777B1 (en)	2007-04-18
HK1098364A1 (en)	2007-07-20
DE602004006009T2 (de)	2008-01-10
DK1677777T3 (da)	2007-09-03
WO2005034930A1 (en)	2005-04-21
CN1882321A (zh)	2006-12-20
ATE359771T1 (de)	2007-05-15
BG109539A (bg)	2006-11-30
HRP20070322T3 (hr)	2007-09-30
AU2004280132A1 (en)	2005-04-21
RS52150B (sr)	2012-08-31
NO20062082L (no)	2006-05-09
DE602004006009D1 (de)	2007-05-31
SI1677777T1 (sl)	2007-10-31
PL1677777T3 (pl)	2007-08-31
CY1106693T1 (el)	2012-05-23
HRP20060136A2 (en)	2006-06-30
EA009695B1 (ru)	2008-02-28
IL174830A0 (en)	2008-04-13
EP1677777A1 (en)	2006-07-12
HUP0303382D0 (en)	2003-12-29
RS20060252A (sr)	2008-08-07
ES2285538T3 (es)	2007-11-16
SK50442006A3 (sk)	2006-08-03

Legal Events

Date	Code	Title	Description
2013-08-30	VOID	Decisions declaring the decisions on the grant of the patent lapsed

Publication	Publication Date	Title
PL1677777T3 (pl)	2007-08-31	Granulki zawierające chlorowodorek venlafaxiny
MX2010013766A (es)	2011-03-15	Rasagilina para modificacion de enfermedad de parkinson.
SG153830A1 (en)	2009-07-29	Galenic formulations of organic compounds
NO20073959L (no)	2007-09-27	Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
MX2010007672A (es)	2010-10-07	Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
JO2973B1 (en)	2016-03-15	Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2006071740A3 (en)	2007-04-19	5ht2c receptor modulator compositions and methods of use
IS2393B (is)	2008-08-15	Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
WO2003072030A3 (en)	2004-01-22	Methods for preventing or treating cardiac arrhythmia
IL177243A0 (en)	2006-12-10	Extended release coated minitablets of venlafaxine hydrochloride
HRP20100373T4 (hr)	2016-12-16	Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima
EA201170784A1 (ru)	2011-12-30	Гранулы тамсулозина для фиксированной комбинации
MX2010003594A (es)	2010-09-22	Formas cristalinas de sal sodica de dmxaa.
MX2007014963A (es)	2008-04-17	Composicion de liberacion modificada de al menos una forma de venlafaxina.
MXPA06000363A (es)	2006-03-28	Forma de dosificacion oral de mesilato de saquinavir.
PL1589014T3 (pl)	2008-01-31	Sposób syntezy pochodnych 1,3-dihydro-2H-3-benzazepin-2-onu i jego zastosowanie do wytwarzania iwabradyny i jej dopuszczalnych farmaceutycznie soli
IL166596A0 (en)	2006-01-15	Salt of morphine-6-glucoronide
SG170037A1 (en)	2011-04-29	Compositions useful for reducing nephrotoxicity and methods of use thereof
GR1004331B (el)	2003-09-05	Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
HUP0303383A2 (hu)	2005-04-28	Piridazinon-származékot tartalmazó pelletek
WO2007069033A3 (en)	2007-10-04	Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol
WO2006011001A3 (en)	2006-05-18	Controlled release compositions of divalproex sodium
MY134311A (en)	2007-12-31	Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol
WO2005115092A3 (en)	2006-03-23	Micronized oral pharmaceutical composition
TNSN06242A1 (en)	2007-12-03	Extended release coated minitablets of venlafaxine hydrochloride